Welcome to LookChem.com Sign In|Join Free


  • or


Post Buying Request

913574-95-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

913574-95-5 Usage

General Description

Cis-1-Cbz-3-fluoro-4-hydroxypiperidine is a chemical compound with potential biological and pharmaceutical applications. It is a piperidine derivative with a fluorine atom attached to the third carbon and a hydroxy group on the fourth carbon, both in the cis configuration. The compound is also protected by a carbobenzyloxy (Cbz) group, which can be removed under specific conditions to reveal the free amine. Cis-1-Cbz-3-fluoro-4-hydroxypiperidine has been studied for its potential use as a building block in medicinal chemistry, particularly in the synthesis of pharmaceuticals and bioactive compounds. Its unique structure and reactivity make it a valuable tool for drug development and chemical synthesis.

Check Digit Verification of cas no

The CAS Registry Mumber 913574-95-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,1,3,5,7 and 4 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 913574-95:
185 % 10 = 5
So 913574-95-5 is a valid CAS Registry Number.



According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017


1.1 GHS Product identifier

Product name benzyl 3-fluoro-4-hydroxypiperidine-1-carboxylate

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:913574-95-5 SDS

913574-95-5Relevant articles and documents



, (2020/06/19)

Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists

Shi, Jun,Gu, Zhengxiang,Jurica, Elizabeth Anne,Wu, Ximao,Haque, Lauren E.,Williams, Kristin N.,Hernandez, Andres S.,Hong, Zhenqiu,Gao, Qi,Dabros, Marta,Davulcu, Akin H.,Mathur, Arvind,Rampulla, Richard A.,Gupta, Arun Kumar,Jayaram, Ramya,Apedo, Atsu,Moore, Douglas B.,Liu, Heng,Kunselman, Lori K.,Brady, Edward J.,Wilkes, Jason J.,Zinker, Bradley A.,Cai, Hong,Shu, Yue-Zhong,Sun, Qin,Dierks, Elizabeth A.,Foster, Kimberly A.,Xu, Carrie,Wang, Tao,Panemangalore, Reshma,Cvijic, Mary Ellen,Xie, Chunshan,Cao, Gary G.,Zhou, Min,Krupinski, John,Whaley, Jean M.,Robl, Jeffrey A.,Ewing, William R.,Ellsworth, Bruce Alan

, p. 681 - 694 (2018/02/16)

G protein-coupled receptor 40 (GPR40) has become an attractive target for the treatment of diabetes since it was shown clinically to promote glucose-stimulated insulin secretion. Herein, we report our efforts to develop highly selective and potent GPR40 agonists with a dual mechanism of action, promoting both glucose-dependent insulin and incretin secretion. Employing strategies to increase polarity and the ratio of sp3/sp2 character of the chemotype, we identified BMS-986118 (compound 4), which showed potent and selective GPR40 agonist activity in vitro. In vivo, compound 4 demonstrated insulinotropic efficacy and GLP-1 secretory effects resulting in improved glucose control in acute animal models.



, (2017/07/14)

The present invention is directed to 6,7-dihydro-5H-pyrrolo[3,4-b]pyridine-5-one compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)


What can I do for you?
Get Best Price

Get Best Price for 913574-95-5